QTTB
Q32 Bio
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 0
EPS Beats Expectation
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About QTTB
Q32 Bio Inc.
A biotechnology company focused on treating autoimmune and inflammatory diseases
830 Winter Street, Waltham, MA 02451
--
Q32 Bio Inc., incorporated in 2015 under the laws of the State of Delaware, is a genetic medicine company dedicated to improving the lives of patients with rare genetic diseases and addressing significant unmet medical needs by treating the underlying causes of the disease. The Company's proprietary platform is designed to utilize adeno-associated virus vectors, or AAVHSCs, derived from human hematopoietic stem cells to accurately and efficiently deliver in vivo genetic medicines in a wide range of genetic diseases through gene therapy or nuclease gene editing. The unique properties of its 15 new AAVHSC proprietary kits enable it to focus on gene editing methods called gene correction, either by replacing entire disease genes in the genome with complete functional copies or precisely repairing individual mutated nucleotides by utilizing homologous recombination of naturally occurring DNA repair processes or HR.
Company Financials
EPS
QTTB has released its 2024 Q4 earnings. EPS was reported at -1.16, versus the expected -1.25, beating expectations. The chart below visualizes how QTTB has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
